One hundred and forty-five elderly patients affected by cerebrovascular diseases were included in the study. Patients were divided into two age-, sex- and clinically matched groups: the first group included 103 patients who were treated for six months with mesoglycan (100 mg/day), whereas the second group, which numbered 42 patients, received standard anti-platelet treatment over the same period. The results of the study confirm the clinical efficacy of mesoglycan compared to standard treatment with antiplatelet drugs in terms of ischemic events and the "quality of life" of cerebrovasculopathic patients.